✦ LIBER ✦

Phase 2 Study of Consolidative Involved-Node Proton Therapy in Patients With Hodgkin Lymphoma: Early Outcomes

✍ Scribed by Hoppe, B.S.; Flampouri, S.; Dang, N.H.; Lynch, J.W.; Morris, C.G.; Li, Z.; Mendenhall, N.P.

Book ID: 123536589
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 60 KB
Volume: 87
Category: Article
ISSN: 0360-3016
DOI: 10.1016/j.ijrobp.2013.06.419

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Consolidative Involved-Node Proton Thera

Consolidative Involved-Node Proton Therapy for Stage IA-IIIB Mediastinal Hodgkin Lymphoma: Preliminary Dosimetric Outcomes From a Phase II Study

✍ Bradford S. Hoppe; Stella Flampouri; Zhong Su; Christopher G. Morris; Naeem Lati 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 565 KB

Involved-Node Proton Therapy in Combined

Involved-Node Proton Therapy in Combined Modality Therapy for Hodgkin Lymphoma: Results of a Phase 2 Study

✍ Hoppe, Bradford S.; Flampouri, Stella; Zaiden, Robert; Slayton, William; Sandler 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 876 KB

46 Significant reduction of second breas

46 Significant reduction of second breast cancer risk in patients treated with involved nodes radiation therapy for early stage Hodgkin's lymphoma

✍ A.R. Filippi; P. Ciammella; C. Fiandra; A. Botticella; R. Ragona; U. Vitolo; A. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Phase 2 study of rituximab plus ABVD in

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

✍ Younes, A.; Oki, Y.; McLaughlin, P.; Copeland, A. R.; Goy, A.; Pro, B.; Feng, L. 📂 Article 📅 2012 🏛 American Society of Hematology 🌐 English ⚖ 664 KB

Phase 2 study of gemcitabine in combinat

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

✍ Yasuhiro Oki; Barbara Pro; Luis E. Fayad; Jorge Romaguera; Felipe Samaniego; Fre 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB 👁 2 views

## Abstract ## BACKGROUND. The management of recurrent or refractory Hodgkin lymphoma (HL) remains challenging. The objective of this phase 2 trial was to investigate the activity of gemcitabine in combination with rituximab in patients with recurring or refractory HL. ## METHODS. Patients were

Predicted Risk of Radiation-Induced Canc

Predicted Risk of Radiation-Induced Cancers After Involved Field and Involved Node Radiotherapy With or Without Intensity Modulation for Early-Stage Hodgkin Lymphoma in Female Patients

✍ Damien C. Weber; Safora Johanson; Nicolas Peguret; Luca Cozzi; Dag R. Olsen 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 395 KB